Drug notes:
ViTRAP platform RD infectious diseases
About:
PineTree Therapeutics is developing novel medicines to combat drug resistance in oncology. To overcome the shortcomings of existing therapies, PineTree is creating targeted protein degraders. This includes PineTree’s AbReptorTM, a transformative modular bi-specific and multi-specific antibody platform designed to degrade membrane-bound and extracellular proteins. AbReptor works by co-engaging a target protein, either surface-receptor or extracellular proteins with another proprietary receptor target. PineTree’s lead candidate, PTX-299, a bispecific antibody for EGFR-driven cancers is not in IND-enabling studies.